Adjuvant therapy for colon cancer 2005: New options in the twenty-first century

Surgical Oncology Clinics of North America

Volumn 15, Issue 1, 2006, Pages 159-173

  Leichman, Cynthia Gail ^a  

^a DESERT REGIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; SEMUSTINE; UFT; VINCRISTINE;

BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; HAND FOOT SYNDROME; HUMAN; INFUSION; LEUKOPENIA; MUCOSA INFLAMMATION; NEUROTOXICITY; REVIEW; RISK REDUCTION; SURVIVAL RATE; TOXICITY;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 29544439250     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2005.09.006     Document Type: Review

References (51)

1. NIH Consensus Conference Adjuvant therapy for patients with colon and rectal cancer JAMA 264 11 1990 1444 1450
2. J.A. Laurie, C.G. Moertel, and T.R. Fleming Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic J Clin Oncol 7 1989 1447 1456
3. C.G. Moertel, T.R. Fleming, and J.S. Macdonald Levamisole and fluorouracil for adjuvant therapy of resected colon cancer N Engl J Med 322 1990 352 358
4. B.G. Taal, H. Van Tinteren, and F.A. Zoetmulder Adjuvant 5-FU plus levamisole in colonic or rectal cancer: improved survival in stage II or III Br J Cancer 85 10 2001 1437 1443
5. P. Thirion, S. Michiels, and J.P. Pignon Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis J Clin Oncol 22 18 2004 3766 3775
6. th Annual Meeting, California; 1998. p. 256a.
7. N. Wolmark, H. Rockette, and B. Fisher The benefit of leucovorin-modulated Fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03 J Clin Oncol 11 10 1993 1879 1887
8. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators Efficacy of adjuvant fluorouracil and folinic acid in colon cancer Lancet 345 8955 1995 939 944
9. M.J. O'Connell, J.A. Laurie, and M. Kahn Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer J Clin Oncol 16 1 1998 295 300
10. W.A. Bleeker, N.H. Mulder, and J. Hermans The addition of low-dose leucovorin to the combination of 5-fluorouracil-levamisole does not improve survival in the adjuvant treatment of Duke's C colon cancer. IKN Colon Trial Group Ann Oncol 11 5 2000 547 552
11. N. Wolmark, H. Rockette, and E. Mamounas Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes'B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04 J Clin Oncol 17 11 1999 3553 3559
12. QUASAR Collaborative Group Comparison of Fluorouracil with additional levamisole, higher dose leucovorin or both as adjuvant chemotherapy for colorectal cancer: a randomized trial Lancet 355 9215 2000 1588 1596
13. C.G. Leichman, T.R. Fleming, and F.M. Muggia Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study J Clin Oncol 13 6 1995 1303 1311
14. P.J. O'Dwyer, J. Manola, and F.H. Valone Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study J Clin Oncol 19 9 2001 2413 2421
15. Meta-analysis Group in Cancer Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 1 1998 301 308
16. A. de Gramont, J.F. Bosset, and C. Milan Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study J Clin Oncol 15 2 1997 808 815
17. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2000 2938 2947
18. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004 229 237
19. T. Andre, P. Colin, C. Louvet, and E. Gamelin Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie radiotherapies Semin Oncol 28 1 Suppl 1 2001 35 40
20. A. Saini, A.R. Norman, and D. Cunningham Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer Br J Cancer 88 12 2003 1859 1865
21. T. Andre, P. Colin, and C. Louvet Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial J Clin Oncol 21 15 2003 2896 2903
22. T. Ishikawa, M. Utoh, and N. Sawada Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts Biochem Pharmacol 55 7 1998 1091 1097
23. T. Browder, C.E. Butterfield, and B.M. Kraling Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 7 2000 1878 1886
24. C.H. Kohne, and G.J. Peters UFT: mechanism of drug action Oncology (Huntingt) 14 10 Suppl 9 2000 13 18
25. W. Scheithauer, J. McKendrick, and S. Begbie X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Ann Oncol 14 12 2003 1735 1743
26. st Annual Meeting Proceedings, Florida; 2004. p. 247s.
27. st Annual Meeting Proceedings. Florida; 2004. p. 247s.
28. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 13 2000 905 914
29. J.Y. Douillard, D. Cunningham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 9209 2000 1041 1047
30. st Annual Meeting Proceedings. Florida; 2004. p. 245s.
31. T. Delaunoit, R.M. Goldberg, and D.J. Sargeant Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxalipaltin: results from Intergroup Trial N9741 Cancer 101 10 2004 2170 2176
32. st Annual Meeting Proceedings. Florida; 2005. p. 246s.
33. st Annual Meeting Proceedings. Florida; 2005. p.3s.
34. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 2004 23 30
35. M.L. Rothenberg, A.M. Oza, and R.H. Bigelow Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 11 2003 2059 2069
36. T. Andre, C. Boni, and L. Mounedji-Boudiaf Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 23 2004 2343 2351
37. st Annual Meeting Proceedings. Florida; 2005. p. 246s.
38. st Annual Meeting Proceedings. Florida; 2005. p. 246s.
39. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345
40. F.F. Kabbinavar, J. Hambleton, and R.D. Mass Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 16 2005 3706 3712
41. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
42. H.I. Hurwitz, L. Fehrenbacher, and J.D. Hainsworth Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 15 2005 3502 3508
43. S. Cascinu, C. Aschele, and S. Barni Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil Clin Cancer Res 5 8 1999 1996 1999
44. H. Elsaleh, B. Powell, and P. Soontrapornchai et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma Oncology 58 1 2000 52 59
45. S. Iqbal, and H.J. Lenz Molecular predictors of treatment and outcome in colorectal cancer Curr Gastroenterol Rep 5 5 2003 399 405
46. st Annual Meeting Proceedings. Florida; 2005. p. 248s.
47. S. Marsh, J.A. McKay, and S. Curran Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis Oncol Rep 9 2 2002 231 234
48. A. Hemminki, J.P. Mecklin, and H. Jarvinen Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy Gastroenterology 119 4 2000 921 928
49. M.R. Kohonen-Corish, J.J. Daniel, and C. Chan Low microsatellite instability is associated with poor prognosis in stage C colon cancer J Clin Oncol 23 10 2005 2318 2324
50. J. Jen, H. Kim, and S. Piantadosi Allelic loss of chromosome 18q and prognosis in colorectal cancer N Engl J Med 331 4 1994 213 221
51. G. Lanza, M. Matteuzzi, and R. Gafa Chromosome 18q allelic loss and prognosis in stage II and III colon cancer Int J Cancer 79 4 1998 390 395